FDA-Approved Use

Mounjaro (tirzepatide) is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Limitations of Use:

• Not studied in patients with a history of pancreatitis.
• Not indicated for the treatment of type 1 diabetes mellitus.

Who Should Not Use Mounjaro

Do not use Mounjaro if:

• You or a family member has ever had medullary thyroid carcinoma (MTC).
• You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• You have a known allergy to tirzepatide or any ingredient in Mounjaro.

How to Use Mounjaro

Mounjaro is injected once weekly under the skin (subcutaneous injection) in the stomach, thigh, or upper arm. Rotate the injection site each week.
It can be taken with or without food.

• Use Mounjaro on the same day each week, at any time of day.
• Do not change your dose or stop using Mounjaro without consulting your healthcare provider.

Before Using Mounjaro — Tell Your Healthcare Provider

Inform your provider about all medications, supplements, and health conditions before starting Mounjaro, including:

• Prescription or over-the-counter medicines
• Vitamins, herbal, or dietary supplements

Important drug interactions include:

• Diabetes medications: Using tirzepatide with insulin or sulfonylureas may increase the risk of low blood sugar.
• Other GLP-1 receptor agonists: Do not combine Mounjaro with medications such as Ozempic, Wegovy, Saxenda, Victoza, Byetta, or Bydureon.
• Oral medications: Mounjaro slows gastric emptying and may affect absorption of oral drugs.
• Hormonal birth control: Oral contraceptives may be less effective during initiation or dose escalation. Use an alternative (non-oral) or barrier contraceptive for 4 weeks after starting Mounjaro and after each dose increase.

Provide your full medical history, especially if you have or have had:

• Type 1 or type 2 diabetes
• Thyroid disorders or thyroid cancer
• Pancreatitis
• Kidney or liver disease
• Gastrointestinal disease or gastroparesis
• Diabetic retinopathy

If you are pregnant or planning to become pregnant, do not use Mounjaro. Weight loss during pregnancy offers no benefit and may harm the unborn baby.

If you are breastfeeding, it is not known whether Mounjaro passes into breast milk. Discuss risks and benefits with your provider.

Providing incomplete or inaccurate medical information may lead to harm or serious complications.